A Study to Assess Safety, Cellular Kinetics and Exploratory Efficacy of Rapcabtagene Autoleucel in Rheumatoid Arthritis and Sjogren's Disease

Who May Qualify: - Signed willing to sign a consent form must be obtained prior to participation in the study - Men and women aged ≥ 18 years and ≤ 75 years at Screening For RA only - Diagnosis of rheumatoid arthritis - Treatment failure of standard of care therapies - Active disease For SjD only - Diagnosis of Sjogren's disease - Active disease Who Should NOT Join This Trial: - BMI at Screening of ≤17 or ≥ 40 kg/m2 - Clinically significant active, opportunistic, chronic or recurrent infection - Sexually active males unwilling to use a condom during intercourse from the time enrollment - Women of childbearing potential, unless they are using a highly effective method of contraception starting from the time of enrollment - Female participants who are pregnant, breastfeeding or intending to conceive during the course of the study - Inyour organs (liver, kidneys, etc.) are working well enough based on blood tests during screening - History of lymphoproliferative disease or any known malignancy or history of malignancy - History of bone marrow/hematopoietic stem cell or solid organ transplantation - Any psychiatric condition or disability making compliance with treatment or willing to sign a consent form impossible Other protocol-defined inclusion/exclusion criteria may apply. Always talk to your doctor about whether this trial is right for you.